SCHEMBL11078710

SCHEMBL11078710

N[C@@](Cc1ccc(O)cc1)(C(=O)O)C(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.57
ODC1 P11926 1/20 0.43
SLC7A5 Q01650 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
PMP22 Q01453 2/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
HIF1A Q16665 1/20 0.42
ESR1 P03372 3/20 0.41
CA2 P00918 2/20 0.41
CAMK2A Q9UQM7 1/20 0.41
KIF11 P52732 1/20 0.40
ARG1 P05089 1/20 0.39
ESR2 Q92731 2/20 0.38
POLB P06746 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11081595 1.00 BLM (0.57) BLMODC1SLC7A5SMN1; SMN2KDM4E
SCHEMBL22074778 0.87 BLM (0.58) BLMSLC7A5SMN1; SMN2KDM4EMAPT
SCHEMBL1274884 0.86 SMN1; SMN2 (0.58) BLMODC1SLC7A5SMN1; SMN2KDM4E
SCHEMBL1274883 0.86 SMN1; SMN2 (0.58) BLMODC1SLC7A5SMN1; SMN2KDM4E
SCHEMBL25578518 0.85 BLM (0.51) BLMSLC7A5KDM4EESR1CA2
SCHEMBL6718873 0.82 KDM4E (0.60) BLMODC1SLC7A5SMN1; SMN2KDM4E
SCHEMBL11574844 0.82 KDM4E (0.60) BLMODC1SLC7A5SMN1; SMN2KDM4E
SCHEMBL11084247 0.81 GRM2 (0.44) BLMODC1SMN1; SMN2KDM4EMAPT
SCHEMBL11493903 0.79 BLM (0.57) BLMSLC7A5SMN1; SMN2KDM4EMAPT
SCHEMBL11493907 0.79 BLM (0.57) BLMSLC7A5SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174460-A1 AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-06-08 US disclosed
US-4483870-A α-Difluoromethyl amino acids and hypertension treating compositions thereof MERCK & CO., INC. (US) 1984-11-20 US disclosed
EP-0007600-B1 ALPHA-DIFLUOROMETHYL AMINO ACIDS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MERCK & CO. INC. (US) 1983-05-11 EP disclosed
EP-0007600-A1 Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same MERCK & CO. INC. (US) 1980-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174460-A1 AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE PARK7, SNCA, RHOT2 BLM 1837/4885ODC1 2130/4885SLC7A5 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.